// Account brief

Gilead

Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source. Covers Gilead Sciences as a whole, including Kite, so Kite releases and job postings count with Gilead's.

Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.

Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.

Scores

Theme Priority (1 to 10) Delivery (0 to 10) Stage Commitments made public, last 12 months R&D roles open on 6 Oct 2026
AI in drug discovery 2 claimed claimed 0 2
Research labs and data No eligible company disclosure identified No eligible company disclosure identified 0 3

The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.

Summary

Gilead scores 2 out of 10 for priority in AI in drug discovery, and delivery is shown as claimed: the company says AI is in use, but the sources show no identifiable system in operation. Its evidence is a stated aim to adopt and scale AI, research data science teams brought together, and a new Research Center at headquarters that opened in September 2026 with added research data science capacity. For research labs and data, no eligible company disclosure was identified. No AI discovery commitment was made public in the last 12 months; the year before brought the Terray Therapeutics collaboration on its tNova platform and the announcement of the Research Center as digitally enabled labs. On 6 October 2026 Gilead had 2 AI in drug discovery roles open, including an AI/ML scientist for biologics design, and 3 research labs and data roles, including a research systems software engineer and a protein therapeutics automation engineer.

AI in drug discovery

What the company says: Priority 2

Gilead will build and maintain leadership capabilities to govern AI responsibly while applying these powerful new tools to support drug discovery, improve the employee experience and expedite responsible business reporting efforts.

2025 Responsible Business and Impact Report, 21 Apr 2026, p. 10

Brings Together Oncology, Inflammation and Research Data Science Teams to Foster Scientific Collaboration

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines, 8 Sep 2026

Adopt and Scale AI to Transform How We Work

2026 Notice of Annual Meeting and Proxy Statement with Form 10-K for FY2025 (annual report wrapper), 20 Mar 2026, p. 2

Gilead recognizes the growing strategic importance of AI to the company's mission to discover, develop and deliver innovative therapeutics

2026 Notice of Annual Meeting and Proxy Statement with Form 10-K for FY2025 (annual report wrapper), 20 Mar 2026, p. 34

Across Gilead, AI is enabling new levels of agility and insight that will continue to shape how we work in 2026 and beyond.

2026 Notice of Annual Meeting and Proxy Statement with Form 10-K for FY2025 (annual report wrapper), 20 Mar 2026, p. 10

What it shows running: Delivery claimed, claimed

today celebrated the opening of its 182,000-square-foot Research Center at its Foster City headquarters, expanding capabilities in oncology, inflammation and research data science

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines, 8 Sep 2026

By co-locating key research disciplines and expanding our data science capabilities, we are strengthening the infrastructure needed to accelerate discovery and advance meaningful innovations.

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines, 8 Sep 2026

Commitments made public in the last 12 months: 0

None identified in the reviewed sources.

Commitments made public in the year before: 1

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 2

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Technology named in these postings

Asked for as experience: Python.

A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.

Research labs and data

No eligible company disclosure identified for this theme in the reviewed sources and period. This is not a finding that the company is inactive.

Commitments made public in the last 12 months: 0

None identified in the reviewed sources.

Commitments made public in the year before: 1

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 3

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Two questions to investigate (Ortent's interpretation)

  1. Who decides on lab automation, scheduling software and LIMS or ELN choices: Research Informatics, departmental automation teams such as Protein Therapeutics, or Kite Research, and does any of the $2 billion Gilead has stated for digital and advanced engineering fund this work?
  2. Who decides whether Gilead licenses an external AI discovery platform, as with Terray, or builds in Research Data Sciences, when research AI roles also sit in the IT Data and AI organisation, and which route do such deals take: Research, business development or IT procurement?

Coverage limits

The investor site returned a Cloudflare challenge, so results slides, webcasts and transcripts were not read, and no 10-K was read for either year. Business Wire, GlobeNewswire, Fierce Biotech, Fierce Pharma and several trade sites blocked access, and the newswire index reached back only to October 2025, so the year before the last 12 months is covered more thinly. A capped search budget left some searches unrun, including checks for Terray and Genesis milestones and for Kite AI collaborations. The lack of a research labs and data disclosure is a search result, not proof that no such work exists.

// GET IN TOUCH

Clarity when it counts.

For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.

Request a 30-minute intro call